Cell Stress and Chaperones

, Volume 16, Issue 2, pp 153–162 | Cite as

Heat shock protein 70 is acute phase reactant: response elicited by tumor treatment with photodynamic therapy

Original Paper

Abstract

Oxidative stress in photodynamic therapy (PDT)-treated tumor cells is known to instigate a strong upregulation of the expression of heat shock proteins. However, the treatment of mouse Lewis lung carcinoma (LLC) cells with Photofrin™ PDT resulted in the upregulation of heat shock protein 70 (Hsp70) gene not only in these cells but also in co-incubated untreated Hepa 1-6 cells. To investigate whether this phenomenon extends in vivo, LLC tumors growing in C57BL/6 mice were treated with Photofrin™ PDT. The tumors and the livers from the mice were collected at 4, 8, or 24 h after therapy for quantitative reverse transcriptase polymerase chain reaction-based analysis of Hsp70 gene expression. Increased Hsp70 gene expression was detected in both the tumor and liver tissues and was most pronounced at 4 h after PDT. This effect was inhibited by treatment of host mice with glucocorticoid synthesis inhibitor metyrapone. Hsp70 protein levels in the livers of mice bearing PDT-treated tumors gradually decreased after therapy while serum levels increased at 4 h after therapy and then continually decreased. The exposure of in vitro PDT-treated LLC cells to Hsp70 and subsequent flow cytometry analysis revealed binding of this protein to cells that was dependent on PDT dose and more pronounced with dying than viable cells. Thus, following the induction of tumor injury by PDT, Hsp70 can be produced in the liver and spleen as acute phase reactant and released into circulation, from where it can be rapidly sequestered to damaged tumor tissue to facilitate the disposal of dying cells.

Keywords

Heat shock proteins Acute phase response Photodynamic therapy Dead tumor cell disposal Glucocorticoid hormones 

References

  1. Arispe N, Doh M, Simakova O, Kurganov B, de Maio A (2004) Hsc70 and Hsp70 interact with phospahatidylserine on the surface of PC12 cells resulting in a decrease of viability. FASEB J 18:1636–1645CrossRefPubMedGoogle Scholar
  2. Asea A (2003) Chaperone-induced signal transduction pathways. Exerc Immunol Rev 9:25–33PubMedGoogle Scholar
  3. Bausero MA, Gastpar R, Multhoff AA (2005) Alternative mechanism by which IFN-γ enhances tumor recognition: active release of heat shock protein 72. J Immunol 175:2900–2912PubMedGoogle Scholar
  4. Calderwood SK, Theriault J, Gray PJ, Gong J (2007) Cell surface receptors for molecular chaperons. Methods 43:199–206CrossRefPubMedGoogle Scholar
  5. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumor immunity. Nat Rev Cancer 6:535–545CrossRefPubMedGoogle Scholar
  6. Chrousos GP (1995) The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351–1362CrossRefPubMedGoogle Scholar
  7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905CrossRefPubMedGoogle Scholar
  8. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefPubMedGoogle Scholar
  9. Gehrmann M, Radons J, Molls M, Multhoff G (2008) The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones 13:1–10CrossRefPubMedGoogle Scholar
  10. Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AMR (1996) Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res 56:2355–2360PubMedGoogle Scholar
  11. Hartl FU, Hayer-Hartl M (2002) Molecular chaperons in cytosol: from nascent chain to folded protein. Science 295:1852–1858CrossRefPubMedGoogle Scholar
  12. Heinrich PC, Castell JV, Andus T (1990) Interleukin 6 and the acute phase response. Biochem J 265:621–636PubMedGoogle Scholar
  13. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55:145–157CrossRefPubMedGoogle Scholar
  14. Huang Z (2005) A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 4:283–294PubMedGoogle Scholar
  15. Korbelik M (2006) PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 38:500–508CrossRefPubMedGoogle Scholar
  16. Korbelik M (2009) Complement upregulation in photodynamic therapy-treated tumors: role of Toll-like receptor pathway and NFκB. Cancer Lett 281:232–238CrossRefPubMedGoogle Scholar
  17. Korbelik M, Merchant S (2008) Hormonal component of tumor photodynamic therapy response. Proc SPIE 6857:051–058Google Scholar
  18. Korbelik M, Sun J, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65:1018–1026PubMedGoogle Scholar
  19. Korbelik M, Cecic I, Merchant S, Sun J (2008) Acute phase response induction by cancer treatment with photodynamic therapy. Int J Cancer 122:1411–1417CrossRefPubMedGoogle Scholar
  20. Krysko DV, D’Herde K, Vandenabeele P (2006) Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11:1709–1726CrossRefPubMedGoogle Scholar
  21. Mahoney JA, Rosen A (2005) Apoptosis and autoimmunity. Curr Opin Immunol 17:583–588CrossRefPubMedGoogle Scholar
  22. Májai G, Petrovski G, Fésüs L (2006) Inflammation and the apopto-phagocytic system. Immunol Lett 104:94–101CrossRefPubMedGoogle Scholar
  23. Manfredi AA, Iannacone M, D’Auria F, Rovere-Querini P (2002) The disposal of dying cells in living tissue. Apoptosis 7:153–161CrossRefPubMedGoogle Scholar
  24. Merchant S, Sun J, Korbelik M (2007) Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer. Photochem Photobiol Sci 6:1284–1289CrossRefPubMedGoogle Scholar
  25. Merchant S, Huang N, Korbelik M (2010) Expression of complement and pentraxin proteins in acute phase response elicited by tumor photodynamic therapy: the engagement of adrenal hormones. Int Immunopharmacol (in press)Google Scholar
  26. Mold C, Gresham HD, Du Clos TW (2001) Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol 166:1200–1205PubMedGoogle Scholar
  27. Molvarec A, Prohaska Z, Nagy B, Kalabay L, Szalay J, Fust G, Karadi I, Rigo J Jr (2006) Association of increased serum heat shock protein 70 and C-reactive protein concentration and decreased serum alpha(2)-HS glycoprotein concentration with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. J Reprod Immunol 73:172–179CrossRefPubMedGoogle Scholar
  28. Nauta AJ, Daha MR, van Kooten C, Roos A (2003) Recognition and clearance of apoptotic cells: a role of complement and pentraxins. Trends Immunol 24:148–154CrossRefPubMedGoogle Scholar
  29. Nimmerjahn F, Ravetch JV (2008) Fcγ receptors as regulators of immune response. Nat Rev Immunol 8:34–47CrossRefPubMedGoogle Scholar
  30. Pockley AG (2003) Heat shock proteins as regulators of the immune response. Lancet 362:469–476CrossRefPubMedGoogle Scholar
  31. Prohászka Z, Singh M, Nagy K, Lakos G, Duba J, Füst G (2002) Heat shock protein 70 is a potent activator of the human complement system. Cell Stress Chaperones 7:17–22CrossRefPubMedGoogle Scholar
  32. Steel DM, Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15:81–88CrossRefPubMedGoogle Scholar
  33. Sun L, Chang J, Kirchhoff SR, Knowlton AA (2000) Activation of HSF and selective increase in heat-shock proteins by acute dexamethasone treatment. Am J Physiol Heart Circ Physiol 278:H1091–H1097PubMedGoogle Scholar
  34. Terry DF, Wyszynski DF, Nolan VG, Atzmon G, Schoenhofen EA, Pennington JY, Andersen SL, Wilcox MA, Farrer LA, Barzilai N, Baldwin CT, Asea A (2006) Serum heat shock protein 70 level as a biomarker of exceptional longevity. Mech Ageing Dev 127:862–868CrossRefPubMedGoogle Scholar
  35. Theriault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK (2005) Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett 579:1951–1960CrossRefPubMedGoogle Scholar
  36. Wu MS, Robbins JC, Bugianesi RL, Ponpipom MM, Shen Y (1981) Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta 674:19–29PubMedGoogle Scholar
  37. Zhou F, Xing D, Chen WR (2008) Dynamics and mechanism of HSP70 translocation induced by photodynamic therapy treatment. Cancer Lett 264:135–144CrossRefPubMedGoogle Scholar
  38. Zhou F, Xing D, Chen WR (2009) Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells. Int J Cancer 125:1380–1389CrossRefPubMedGoogle Scholar

Copyright information

© Cell Stress Society International 2010

Authors and Affiliations

  1. 1.British Columbia Cancer AgencyB.C. Cancer Research CentreVancouverCanada

Personalised recommendations